Amarna Announces Research Collaboration for Testing MS Gene Therapy Platform

Amarna Announces Research Collaboration for Testing MS Gene Therapy Platform
4.8
(12)

Dutch Amarna Therapeutics announced a research collaboration with Spanish Progreso y Salud Foundation (FPS) to investigate the efficacy of its gene therapy delivery technology in multiple sclerosis (MS) and diabetes.

MS is thought to be caused by immune-mediated inflammation that damages myelin — an insulating sheath around nerve cells whose loss is the hallmark of MS. The new partnership between the biotech company and the foundation’s research group aims to assess the efficacy of Amarna’s viral-based gene delivery vector in reducing the immune responses that trigger the damage and loss of myelin in animal models of MS.

The research also will assess the vehicle’s effectiveness in animal models of diabetes mellitus type 1.

“We are thrilled to start this new venture with Amarna Therapeutics, a world leader in viral gene therapy and we anticipate the studies to generate exciting results,” Benoit Gauthier, a staff scientist at Junta de Andalucia-Consejeria de Salud y Familias, said in a press release.

The research partnership is led by Gauthier, PhD, at the FPS in Seville, Spain, together with Peter de Haan, PhD, Amarna’s chief scientific officer, and Miguel García Toscano, PhD, head of R&D of Amarna in Spain.

Preventing the immune attack against myelin in MS — a process called immune tolerance — can be achieved using gene therapy, in which myelin antigens (molecules that can trigger an immune response) are introduced into cells using a viral vector (vehicle). The aim is to desensitize the immune system’s response against these antigens.

Amarna has developed a viral vector called SVecTM as a gene delivery platform technology. This platform is based on the Simian virus 40 (SV40), which is non-immunogenic or tolerogenic to humans — meaning the virus does not trigger an immune response.

“The non-immunogenicity also named tolerogenicity in humans renders SV40 vectors highly attractive for use in gene therapy and immunotherapies,” Amarna states in its website.

Amarna will invest around 600,000€ (about $700,00) over the next two years in Gauthier’s research to conduct proof-of-principle studies using animal models of MS and diabetes mellitus type 1.

“We are delighted entering this collaboration with such a renowned academic partner like FPS and we look very much forward to initiate the planned studies,” de Haan said.

“Since the quality of life for patients with [diabetes mellitus type 1] and MS is so severely impaired given the lack of cures for these … diseases, the more efficiently we can develop our groundbreaking SV40-based gene delivery vector based therapies, the sooner patients will experience the positive impact of our solution on their lives,” de Haan added.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 1,053
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • myelin study
  • dental amalgam
  • Amarna gene therapy platform
  • mental disorders in MS

How useful was this post?

Click on a star to rate it!

Average rating 4.8 / 5. Vote count: 12

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?